Author: Jesse Landry

The ocean does not negotiate. It does not care about quarterly earnings calls, press cycles, or how confident your deck looks on slide 12. It moves on physics, pressure, and patience. That is the frame Apeiron Labs chose to build from, and now the market has responded with $9.5M Series A capital that feels less like a splash and more like a deep, deliberate current forming underneath the surface. Apeiron Labs was founded in 2022 with a simple but uncomfortable observation. Humanity knows more about the surface of Mars than the upper layers of its own oceans. Ravi Pappu, CEO,…

Read More

Most finance software talks about clarity like it is a destination. Una Software treats it like a discipline. You earn it, quarter after quarter, forecast after forecast, when the numbers stop arguing with reality and start explaining it. That is the quiet flex behind Una Software closing $13M in total funding, with Staircase Ventures leading and Janet Bannister backing the conviction that modern finance teams deserve tools that think as fast as the business moves. Una Software did not show up in 2023 trying to charm CFOs with prettier dashboards. Don Mal and Clayton Ramnarine showed up with scars from…

Read More

Websites were never meant to be alive. They were meant to sit still, smile politely, and hope someone clicked the right thing. Then marketing teams duct-taped analytics to them, agencies piled on experiments, engineers got dragged into endless tweaks, and everyone pretended this was optimization. The internet shrugged. Customers bounced. The page stayed dumb. Fibr AI starts with a different assumption. A website is not a brochure. It is a system. A living one. One that listens, learns, adapts, and responds in real time, not after a quarterly deck and 6 approvals. That belief just pulled in $5.7M in seed…

Read More

There is a moment in every security leader’s career when the dashboards keep blinking, the alerts keep piling up, and the organization realizes the problem is not a lack of tools. It is a lack of intelligence that can actually think. Airrived Inc. did not wander into that moment by accident. It was built inside it, with scars, receipts, and a clear sense that enterprise security needed less theater and more cognition. Airrived just came out of stealth with a $6.1M seed round, and the number matters less than the intent behind it. Cannage Capital led the round, with Shelley…

Read More

Graici lives squarely in the second camp. Born in 2021 as a spin-out from Unify Labs, Graici did not come from a brainstorm; it came from friction. Stephen McHale has spent decades watching systems fail quietly while people pay loudly, and this company is the byproduct of refusing to normalize that failure. This week, Graici closed a $7.5M Series A led by Santé Ventures, with continued support from North Coast Ventures, JumpStart Ventures, OVO Fund, University Hospitals Ventures, and Unify Labs. On paper, it brings total funding to $15M. In practice, it buys leverage against a Medicaid system that just…

Read More

There is a moment in every industrial cycle where the noise drops out and you can hear the machine breathe. That moment usually arrives right before something important happens. In February 2026, Machina Labs caught that silence and filled it with $124M in Series C capital, led by Woven Capital, with Lockheed Martin Ventures back in the mix, joined by Balerion Space Ventures and Strategic Development Fund. Not a flex. A signal. Manufacturing is done waiting for permission. Machina Labs was never about shiny robots for demo day. This company came up in the real world, where tooling costs hit…

Read More

The noise around AI is getting louder while the signal keeps hiding in plain sight. Boards want agents. Decks promise leverage. Roadmaps swell with experiments that never quite earn the right to stay. This is the pressure point of the startup ecosystem right now. Not whether AI works, but who knows how to wield it without letting systems decay under their own ambition. Tooling is everywhere. Judgment is rare. That imbalance is where real risk lives. Gather.dev is responding to that moment by convening its people in San Francisco on February 10 for CTOs at Scale and Startup CTOs: Agentic…

Read More

There is a quiet tension running through engineering right now. Not panic, not hype. A low-grade signal that the old mechanics of shipping, hiring, and scaling are starting to strain under new weight. Agentic systems are no longer parlor tricks or late-night demos. They are moving into backlogs, roadmaps, and board-level conversations. In the startup ecosystem, this is the phase where tools stop being toys and start becoming liabilities if misunderstood. That pressure is what pulls people into rooms like this. On Tuesday, February 10, 2026, a focused group of startup CTOs will gather in San Francisco’s Financial District for…

Read More

The quiet tension right now is not about whether AI works. That argument is settled. The real friction inside the startup ecosystem is about control, trust, and taste. What happens when systems designed to accelerate builders begin making decisions faster than the people accountable for the outcome. Founders feel it when velocity turns into entropy. CTOs feel it when experimentation drifts too close to production. This is the stretch where curiosity either matures into discipline or compounds into technical debt that shows up when the stakes are highest. That pressure is why Founding CTOs (SF): Agentic Experiments lands the way…

Read More

Abivax is the kind of company that makes markets nervous because it refuses to behave like a story stock. It was born in December 2013 out of three French biotechs stitched together by Truffle Capital in Paris, with Philippe Pouletty betting that immune balance would matter more than immune suppression. For years, Abivax moved quietly, working on antivirals, learning the hard way, taking punches in public markets, and building real science while most people stopped paying attention. The turn came in a Montpellier lab when obefazimod, first designed for HIV, showed something else entirely. By enhancing microRNA-124, it did not…

Read More